Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis

Published:2022-07-14 Issue:3 Volume:32 Page:473-495
ISSN:2541-9617
Container-title:PULMONOLOGIYA
language:
Short-container-title:Pulʹmonologiâ (Mosk.)

Author:

Avdeev S. N.¹^ORCID,Aisanov Z. R.²^ORCID,Belevskiy A. S.²^ORCID,Ilkovich M. M.³^ORCID,Kogan E. A.⁴,Merzhoeva Z. M.⁴^ORCID,Petrov D. V.⁵,Samsonova M. V.⁶^ORCID,Terpigorev S. A.⁷,Trushenko N. V.¹^ORCID,Trofimenko I. N.⁸^ORCID,Tyurin I. E.⁹^ORCID,Chernyaev A. L.¹⁰^ORCID,Chernyak B. A.¹¹^ORCID,Chernyak A. V.⁶^ORCID,Chikina S. Yu.⁴^ORCID,Chuchalin A. G.²^ORCID,Shmelev E. I.¹²^ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

2. Pirogov Russian National Research Medical University (Pirogov Medical University), Ministry of Health of the Russian Federation

3. Federal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation

4. Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

5. Budgetary Healthcare Institution, Omsk region “City Clinical Hospital No.1 named after Kabanov A.N.”

6. Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia

7. M.F.Vladimirskiy State Moscow Regional Research Clinical Institute

8. Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuing Professional Education”, Healthcare Ministry of the Russian Federation

9. Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia

10. Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Pirogov Russian National Research Medical University (Pirogov Medical University), Ministry of Health of the Russian Federation; Avtsyn Research Institute оf Human Morphology оf Federal State Budgetary Scientific Institution “Petrovsky National Research Centre оf Surgery”

11. Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of Irkutsk State Medical Academy of Postgraduate Training

12. Federal Central Research Institute of Tuberculosis

Abstract

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrotic interstitial pneumonia with a progressive course and poor prognosis. The prevalence of IPF in the Russian Federation is about 8 – 12 cases per 100,000 population. The basic treatment of IPF is antifibrotic agents.Methodology. The target audience of these clinical recommendations are therapists, general practitioners, pulmonologists, pathologists, radiologists, and medical rehabilitation doctors. Each thesis-recommendation about diagnostic and therapeutic procedures has been scored according to the scale of classes of recommendations from 1 to 5 and A, B, C scale of the levels of evidence. Clinical recommendations also contain comments and explanations to the theses, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials.Conclusion. The presented clinical guidelines cover current information about the etiology and pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of idiopathic pulmonary fibrosis. These guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2021.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Subject

Pulmonary and Respiratory Medicine

Reference117 articles.

1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI: 10.1164/rccm.2009-040GL.

2. Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of Idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192 (2): e3–19. DOI: 10.1164/rccm.201506-1063ST.

3. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI: 10.1164/rccm.201308-1483ST.

4. Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79 (1): 149–154. DOI: 10.1086/504639.

5. Allen R.J., Porte J., Braybrooke R. et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir. Med. 2017; 5 (11): 869–880. DOI: 10.1016/S2213-2600(17)30387-9.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possibilities for predicting the course of fibrosing interstitial lung diseases based on a comprehensive study of the cardio-respiratory system;Regional blood circulation and microcirculation;2024-04-06

2. The potential use of N-acetylcysteine in respiratory conditions;PULMONOLOGIYA;2024-01-31

3. The effectiveness of early administration of antifibrotic therapy as a reflection of properly organized medical care for patients with progressive pulmonary fibrosis;PULMONOLOGIYA;2024-01-26

4. Analysis of expression profile of long non-coding RNA in patients with idiopathic and COVID-19-induced pulmonary fibrosis;Creative surgery and oncology;2023-12-06

5. Biomarkers of Progressive Fibrosing Interstitial Lung Diseases;Innovative Medicine of Kuban;2023-11-16